Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

被引:253
作者
Kabashima, Kenji [1 ]
Matsumura, Takayo [2 ]
Komazaki, Hiroshi [3 ]
Kawashima, Makoto [4 ]
机构
[1] Kyoto Univ, Dept Dermatol, Grad Sch Med, Kyoto, Japan
[2] Maruho, Dept Clin Dev, Kyoto, Japan
[3] Maruho, Dept Data Sci, Kyoto, Japan
[4] Tokyo Womens Med Univ, Tokyo, Japan
关键词
SEVERITY INDEX; INTERLEUKIN-31; RECEPTOR; EUROPEAN GUIDELINES; OBJECTIVE SCORAD; ECZEMA AREA; MANAGEMENT; DUPILUMAB; PLACEBO; ADULTS; VALIDATION;
D O I
10.1056/NEJMoa1917006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundNemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis. MethodsIn a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents in a 2:1 ratio to receive subcutaneous nemolizumab (60 mg) or placebo every 4 weeks until week 16, with concomitant topical agents. The primary end point was the mean percent change in the visual-analogue scale (VAS) score for pruritus (range, 0 to 100, with higher scores indicating worse pruritus) from baseline to week 16. Secondary end points included the time course of change in the VAS score for pruritus up to week 4, the change in the Eczema Area and Severity Index (EASI) score (range, 0 to 72, with higher scores indicating greater severity), a score of 4 or less on the Dermatology Life Quality Index (DLQI; range, 0 to 30, with higher scores indicating a greater effect on daily life), a score of 7 or less on the Insomnia Severity Index (ISI; range, 0 to 28, with higher scores indicating greater severity), and safety. ResultsA total of 143 patients were randomly assigned to receive nemolizumab and 72 to receive placebo. The median VAS score for pruritus at baseline was 75. At week 16, the mean percent change in the VAS score was -42.8% in the nemolizumab group and -21.4% in the placebo group (difference, -21.5 percentage points; 95% confidence interval, -30.2 to -12.7; P<0.001). The mean percent change in the EASI score was -45.9% with nemolizumab and -33.2% with placebo. The percentage of patients with a DLQI score of 4 or less was 40% in the nemolizumab group and 22% in the placebo group; the percentage of patients with an ISI score of 7 or less was 55% and 21%, respectively. The incidence of injection-related reactions was 8% with nemolizumab and 3% with placebo. ConclusionsIn this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents. The incidence of injection-site reactions was greater with nemolizumab than with placebo. Longer and larger trials are necessary to determine whether nemolizumab has a durable effect and is safe for atopic dermatitis. (Funded by Maruho; JapicCTI number, 173740.) In a 16-week, randomized trial involving patients with atopic dermatitis, the monoclonal antibody nemolizumab was more effective than placebo for the relief of pruritus. The incidence of injection-site reactions was higher with nemolizumab than with placebo.
引用
收藏
页码:141 / 150
页数:10
相关论文
共 40 条
[1]  
[Anonymous], 2012, REGEN MED S3, V7, pS14
[2]  
Avena-Woods C, 2017, AM J MANAG CARE, V23, pS115
[3]   IL-31: A new key player in dermatology and beyond [J].
Bagci, Isin Sinem ;
Ruzicka, Thomas .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (03) :858-866
[4]   Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme [J].
Barbier, N ;
Paul, C ;
Luger, T ;
Allen, R ;
De Prost, Y ;
Papp, K ;
Eichenfield, LF ;
Cherill, R ;
Hanifin, J .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (01) :96-102
[5]   Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data [J].
Basra, M. K. A. ;
Salek, M. S. ;
Camilleri, L. ;
Sturkey, R. ;
Finlay, A. Y. .
DERMATOLOGY, 2015, 230 (01) :27-33
[6]   Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].
Blauvelt, Andrew ;
de Bruin-Weller, Marjolein ;
Gooderham, Melinda ;
Cather, Jennifer C. ;
Weisman, Jamie ;
Pariser, David ;
Simpson, Eric L. ;
Papp, Kim A. ;
Hong, H. Chih-Ho ;
Rubel, Diana ;
Foley, Peter ;
Prens, Errol ;
Griffiths, Christopher E. M. ;
Etoh, Takafumi ;
Pinto, Pedro Herranz ;
Pujol, Ramon M. ;
Szepietowski, Jacek C. ;
Ettler, Karel ;
Kemeny, Lajos ;
Zhu, Xiaoping ;
Akinlade, Bolanle ;
Hultsch, Thomas ;
Mastey, Vera ;
Gadkari, Abhijit ;
Eckert, Laurent ;
Amin, Nikhil ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Stahl, Neil ;
Yancopoulos, George D. ;
Shumel, Brad .
LANCET, 2017, 389 (10086) :2287-2303
[7]   The multidimensional burden of atopic dermatitis An update [J].
Bridgman, Alanna C. ;
Block, Julie K. ;
Drucker, Aaron M. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 120 (06) :603-606
[8]   The patient-oriented eczema measure - Development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective [J].
Charman, CR ;
Venn, AJ ;
Williams, HC .
ARCHIVES OF DERMATOLOGY, 2004, 140 (12) :1513-1519
[9]   Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis [J].
Chopra, R. ;
Vakharia, P. P. ;
Sacotte, R. ;
Patel, N. ;
Immaneni, S. ;
White, T. ;
Kantor, R. ;
Hsu, D. Y. ;
Silverberg, J. I. .
BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) :1316-1321
[10]   Relationship between itch and psychological status of patients with atopic dermatitis [J].
Chrostowska-Plak, D. ;
Reich, A. ;
Szepietowski, J. C. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (02) :E239-E242